| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6013531 | Epilepsy & Behavior | 2012 | 5 Pages |
Abstract
⺠LEV PK was evaluated in a phase 2 study in TBI patients with high risk of PTE. ⺠LEV 55 mg/kg/d was given â¤Â 8 h after TBI for 30 days, with PK done on days 3/30. ⺠PK was similar to PK in chronic epilepsy patients, across different administration routes and across ages. ⺠Plasma levels were similar to those seen in positive animal antiepileptogenic studies. ⺠The study lays the groundwork for LEV evaluation in a phase 3 study of PTE prevention.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Pavel Klein, Daniel Herr, Phillip L. Pearl, JoAnne Natale, Zachary Levine, Claude Nogay, Fabian Sandoval, Stacey Trzcinsky, Shireen M. Atabaki, Tammy Tsuchida, John van den Anker, Steven J. Soldin, Jianping He, Robert McCarter,